natgillin/translations-raw huggingface dataset:
Cough Rhinorrhoea Dry throat Dyspnoea
Kašalj Rinoreja Suhoća grla Dispneja
Cough was common, but usually of mild intensity.
Kašalj je bio čest, ali obično blagog intenziteta.
Cough was reported with use of TOBI Podhaler in clinical studies.
Kašalj je zabilježen uz primjenu TOBI Podhalera u kliničkim ispitivanjima.
Cough was very commonly reported with use of Bronchitol in clinical studies (see section 4.8).
Klinička ispitivanja pokazala su vrlo učestalu pojavu kašlja kod primjene Bronchitola (vidjeti dio 4.8).
Cough which could include chest tightness or pain, nasal congestion (bronchitis)
Kašalj koji može uključivati stezanje ili bol u prsnom košu, začepljen nos (bronhitis)
Cough which led to cessation of treatment was also commonly experienced and was observed in 4.7% of patients in the Bronchitol treatment arm.
Učestala pojava bio je i kašalj koji je uzrokovao prekid terapije i primijećen je u 4,7% pacijenata iz skupine koja je liječena Bronchitolom.
Cough with phlegm, chest pain, fever, signs of inflammation of airways (bronchitis viral)
Kašalj sa iskašljajem, bol u prsima, vrućica, znakovi upale dišnih puteva (virusni bronhitis)
Cough with sputum
Kašalj s iskašljajem
Cough †
kašalj
Cough*, dyspnoea*
kašalj*, dispneja
cough,
kašalj
cough,
kašalj,
Cough, breathing difficulties, difficulties speaking, sore throat or mouth, hoarseness, dry mouth, hiccough, inflammation of the mucous membranes;
Kašalj, otežano disanje, otežan govor, bolno grlo ili usta, promuklost, suha usta, štucavica, upala sluznica;
cough, breathing problems
kašalj, problemi s disanjem
cough, chest discomfort/tightness, shortness of breath
kašlja, nelagode/stezanja u prsima, nedostatka zraka
cough, chest pain or tightness, hoarseness, sore or tight throat, sticky throat secretions, runny nose, cold symptoms
kašalj, bol ili stezanje u prsnom košu, promuklost, grlobolja ili stezanje u grlu, ljepljiv sekret iz grla, curenje nosa, simptomi prehlade
Cough, difficulty in breathing (dyspnoea)
kašalj, otežano disanje (dispneja)
cough, dry mouth, pharyngitis (sore throat),
kašalj, suha usta, faringitis (upala grla),
Cough, dyspnoea, rhinorrhoea
Kašalj, dispneja,
Cough, epistaxis
kašalj, epitaksa
Cough, epistaxis exertional dyspnoea
kašalj, epistaksa, dispneja u naporu
cough, epistaxis, hiccups, nasal congestion, pleuritic pain,
kašalj, epistaksa, štucanje, kongestija nosa, pleuralna bol,
cough, epistaxis, hiccups, nasal congestion, pleuritic pain,
kašalj, epistaksa, štucavica, kongestija nosa, pleuralna bol,
Cough, epistaxis, pneumonitis
Kašalj, epistaksa, pneumonitis
Cough, excessive or viscous mucus in the breathing passage, asthma attack in asthmatic patients or patients with a history of asthma
kašalj, obilata ili gusta sluz u dišnim putevima, napad astme u bolesnika s astmom ili u bolesnika koji su imali astmu
cough, feeling short of breath, infection of the sinuses, throat, airway or lungs, chest infections problem with sleeping or falling asleep
kašalj, osjećaj nedostatka zraka, infekcija sinusa, grla, dišnih putova ili pluća, infekcije prsnog koša poteškoće sa spavanjem ili poteškoće prilikom usnivanja
Cough, fever and difficult or painful breathing can be signs of serious pulmonary side effects, such as pneumonia and acute respiratory distress syndrome, which may be fatal.
Kašalj, vrućica i otežano ili bolno disanje mogu biti znakovi ozbiljnih plućnih nuspojava poput upale pluća i akutnog respiratornog distresnog sindroma koji mogu biti smrtonosni.
Cough, fever and difficult or painful breathing can be signs of uncommon (may affect up to 1 in 100 people) serious pulmonary side effects, such as pneumonia and acute respiratory distress syndrome, which may be fatal.
Kašalj, vrućica i otežano ili bolno disanje mogu biti znakovi manje čestih (mogu se javiti u do 1 na 100 osoba), ozbiljnih plućnih nuspojava, kao što su upala pluća i akutni respiratorni distres- sindrom, koji mogu imati smrtni ishod.
Cough, having difficulty breathing or painful breathing (signs of lung problems).
kašalj, otežano disanje ili bolno disanje (znakovi plućnih problema).
cough, hiccups
kašalj, štucanje
cough, hiccups
kašalj, štucavica
cough, hiccups
kašalj, štucavica,
cough, hoarseness, throat tightness, dyspnoea, nasopharyngitis, pharyngitis, throat secretion increased, rhinorrhoea
kašalj, promuklost, stezanje u grlu, dispneja, nazofaringitis, faringitis, povećana sekrecija u grlu, rinoreja
cough, irritated or runny nose
kašalj, nadražen nos ili curenje iz nosa
cough, mucus in back of throat, throat irritation, sneezing, sore throat,
kašalj, cijeđenje sluzi iz nosa u grlo, nadraženo grlo, kihanje, upala grla,
cough, mucus in back of throat, throat irritation, sneezing, sore throat,
kašalj, slijevanje sluzi iz nosa u grlo, iritacija grla, kihanje, upala grla,
cough, mucus in back of throat, throat irritation, sneezing, sore throat,
kašalj, slijevanje sluzi u grlo, iritacija grla, kihanje, upala grla,
cough, mucus in the back of the throat, throat irritation, sneezing, sore throat
kašalj, slijevanje sluzi u grlo, nadraženost grla, kihanje, upala grla
cough, nasal congestion
hiperemija oka
cough, nasal congestion
kašalj, nazalna
cough, nasal congestion
kašalj, nazalna kongestija
Cough, Nasal congestion, Respiratory congestion, Rhinorrhoea
kašalj, kongestija nosa, respiratorna kongestija, rinoreja
Cough, productive cough, voice alteration (hoarseness)
Kašalj, kašalj uz iskašljavanje sadržaja, promjenu glasa (promuklost)
Cough, Rhinitis
kašalj, rinitis
Cough, rhinorrhoea, asthma, nasal congestion, oropharyngeal pain, dyspnea
kašalj, rinoreja, astma, kongestija nosa, orofaringealna bol, dispneja
cough, shortness of breath
kašalj, nedostatak zraka
cough, shortness of breath, chest discomfort or pain, inflammation of nasal passage and/or throat (upper respiratory tract infection), bronchitis
kašalj, nedostatak daha, nelagoda ili bolovi u prsištu, upala nosne sluznice i/ili grla (infekcija gornjega dišnog sustava), bronhitis
cough, sneezing, catarrh or cold, changes in the fluid produced by your nose
kašalj, kihanje, upala sluznice nosa i ždrijela ili prehlada, promjene u izgledu tekućine koju ispuhujete iz nosa
Cough, sore throat
Kašalj, grlobolja
Cough, Sore throat, Rhinorrhea
kašalj, grlobolja, rinoreja
cough, stuffy nose
kašalj, začepljen nos
Cough, throat irritation
kašalj, nadražaj grla
Cough, throat irritation
kašalj, nadraženost grla
cough, trouble breathing or rapid breathing
kašalj, teško disanje ili ubrzano disanje
Cough.
Kašalj
Cough/productive cough,
kašalj / produktivni kašalj
Cough2
Kašalj2
cough2, nasal symptoms1
kašalj2, nosni simptomi1
Cough3
Kašalj3
cough;
kašalj,
cough;
kašalj;
Cough; lung infection with or without fever.
kašalj; upala pluća sa ili bez vrućice
cough; runny nose
kašalj, curenje nosa
cough; sore throat;
kašalj, grlobolja;
Cougha Dyspnoea
kašalja dispneja
Coughd
Kašaljd
coughing
kašalj
coughing
kašljanje
Coughing of blood or blood stained sputum
Iskašljavanje krvi ili krvavog sputuma
Coughing of blood or blood stained sputum
Kašljanje krvi ili krvavnog sputuma
Coughing of blood or blood stained sputum
Kašljanje krvi ili krvavog sputuma
coughing or shortness of breath
kašalj ili nedostatak zraka
coughing or wheezing
kašljanje ili piskanje pri disanju
coughing up blood
iskašljavanje krvi
coughing up blood (common side effect),
iskašljavanje krvi (česta nuspojava)
coughing up blood (haemoptysis)
iskašljavanje krvi (hemoptiza)
Coughing up blood (very common)
Iskašljavanje krvi (vrlo često)
Coughing up blood or blood in your sputum.
Iskašljavanje krvi ili krv u sputumu.
Coughing up blood or blood-stained mucus from the airways.
iskašljavanje krvi ili sluzi s tragovima krvi iz dišnih puteva
coughing up blood, producing more sputum than normally, chest discomfort, asthma, fever
iskašljavanje krvi, nakupljanje više ispljuvka nego obično, nelagoda u prsnom košu, astma, vrućica
coughing up of blood or blood clots
iskašljavanje krvi ili krvnih ugrušaka
Coughing up of blood.
iskašljavanje krvi.
coughing, sore nose
kašalj, bolnost nosa
coughing.
kašljanje
Coughing;
kašalj,
Coughj
kašaljj
could be signs of a severe allergic reaction. experience puffiness in your face or ankles, blood in your urine or brown-coloured urine or you notice you urinate less than usual.
Iskusite natečenost lica ili gležnjeva, krv u urinu i smeđe obojeni urin ili uočite da manje mokrite nego uobičajeno.
coumarin anticoagulants for thinning the blood ( e.g. warfarin)
kumarinske antikoagulanse za razrjeđivanje krvi (npr. varfarin)
coumarin anticoagulants statins
kumarinskim antikoagulansima statinima
Coumarin-derivative anticoagulant
Antikoagulansi - derivati kumarina
Coumarin-derivative anticoagulants.
Kumarinski antikoagulansi
coumarin-type anticoagulants, such as warfarin or phenprocoumon,
kumarinske antikoagulanse, kao što su varfarin ili fenprokumon,
Counselling of patients: This section will emphasise the importance of a thorough, informative and ongoing dialogue between patient and healthcare professional about the pregnancy risks associated with mycophenolate mofetil and the relevant minimisation strategies including alternative treatment choices, if applicable.
Savjetovanje bolesnika: U ovom će se dijelu naglasiti važnost iscrpnog, informativnog i neprekidnog dijaloga između bolesnika i zdravstvenog radnika o riziku od trudnoće kod primjene mofetilmikofenolata te značajnim strategijama za minimizaciju tog rizika, uključujući druge terapijske opcije, ako one postoje.
Count each half of the strip with a suitable radioactivity counting apparatus (dose calibrator or multichannel analyzer).
Izbrojite svaku polovicu trakice odgovarajućim uređajem za brojanje radioaktivnosti (kalibrator doze ili analizator multikanala).
count increased, platelet
povišena kreatinin fosfokinaza u krvi
Count slowly to 15 seconds for injection to end.
Lagano brojite 15 sekundi dok ne završite s davanjem injekcije.
COUNT TO FIVE to ensure that all of the solution is injected.
IZBROJITE DO 5 kako biste bili sigurni da ste injicirali cijelu količinu otopine.
Countries Period (Age)
Zemlje Period (Dob)
Country (year of introduction)
Zemlja (godina uvođenja cjepiva)
Counts (activity) in bottom half Counts(activity) in bottom half + Counts(activity) in top half
Brojevi (aktivnost) u donjoj polovici Brojevi (aktivnost) u donjoj polovici + Brojevi (aktivnost) u gornjoj polovici
Counts (percentages) corresponds to the number of patients reporting the event
Not Elsewhere Classified) Brojevi (postoci) odgovaraju broju bolesnika koji su prijavili događaj
County Durham DL12 8DT United Kingdom.
County Durham DL12 8DT Ujedinjeno Kraljevstvo.
County Durham DL12 8DT United Kingdom.
County Durham DL12 8DT, Ujedinjeno Kraljevstvo.
County Durham DL12 8DT, United Kingdom.
County Durham DL12 8DT, Ujedinjeno Kraljevstvo.
County Durham, DL12 8DT United Kingdom.
County Durham DL12 8DT, Ujedinjeno Kraljevstvo.
Cover
Zatvarač
Cover letter to the healthcare professional;
Popratno pismo za zdravstvenog radnika;
Cover the tank and allow to equilibrate for at least 5 minutes.
Spremnik poklopite i pričekajte najmanje 5 minuta za uravnoteženje (ekvilibraciju).
Cox model (adjustment for Primary tumour site, T and N clinical stages and PSWHO)
Coxov model (prilagodba prema primarnom tumorskom mjestu, T i N kliničkom stupnju te
COX-2 inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects.
Inhibitori COX-2 ne mogu zamijeniti acetilsalicilnu kiselinu kod profilakse kardiovaskularnih tromboembolijskih bolesti zato što nemaju antitrombocitne učinke.
COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function).
COX-2 također je uključen u ovulaciju, implantaciju i zatvaranje ductus arteriosusa, regulaciju funkcije bubrega i funkcije središnjeg živčanog sustava (indukcija vrućice, percepcija bola i kognitivne funkcije).
COX-2 is also thought to be involved in ovulation, implantation and closure of the ductus arteriosus, and central nervous system functions (fever induction, pain perception and cognitive function).
Za COX-2 se također smatra da sudjeluje u ovulaciji, implantaciji i zatvaranju ductus arteriosus, i u funkcijama središnjeg živčanog sustava (početak povišene temperature, prepoznavanje boli i kognitivne funkcije).
COX-2 is the inducible form of the enzyme and is responsible for the production of mediators including PGE2 which induce pain, inflammation or fever.
COX-2 je inducibilni oblik enzima odgovoran za generiranje medijatora uključujući PGE2 koji inducira bol, upalu ili groznicu.
COX-2 is the inducible form of the enzyme which is responsible for the production of mediators including PGE2 which induce pain, inflammation or fever.
COX-2 je inducibilni oblik enzima odgovoran za generiranje medijatora uključujući PGE2 koji induciraju bol, upalu ili groznicu.
COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.
Selektivni inhibitori COX-2 smanjuju stvaranje sistemskog (pa stoga moguće i endotelijalnog) prostaciklina bez utjecanja na trombocitni tromboksan.
COXEVAC suspension for injection for cattle and goats
COXEVAC, injekcijska suspenzija za goveda i koze
Coxevac was initially authorised under ‘exceptional circumstances’.
Coxevac je prvotno odobren pod „iznimnim okolnostima“.
Cox’s Proportional Hazard Ratio [95% CI]
Coxov omjer proporcionalnih rizika [95% CI]
Co–administration may result in decreased plasma concentrations of indinavir and as a consequence an increased risk for suboptimal treatment and facilitation of development of resistance (see section 4.5).
Istodobna primjena može dovesti do smanjene koncentracije indinavira u plazmi, čime se povećava rizik od suboptimalnog liječenja i olakšava razvoj rezistencije (vidjeti dio 4.5).
Co–administration of CRIXIVAN with sildenafil, tadalafil and vardenafil (PDE5 inhibitors) are expected to substantially increase the plasma concentrations of these compounds and may result in an increase in PDE5 inhibitor–associated adverse events, including hypotension, visual changes, and priapism (see section 4.5).
Očekuje se da bi istodobna primjena lijeka CRIXIVAN sa sildenafilom, tadalafilom i vardenafilom (inhibitorima PDE5) mogla značajno povisiti koncentracije navedenih spojeva u plazmi i dovesti do povećanja broja nuspojava povezanih s inhibitorima PDE5, uključujući hipotenziju, promjene vida i prijapizam (vidjeti dio 4.5).
CP 1 g/m2 i.v. (1 h), days 26, 46;
CP 1 g/m2 i.v. (1 h), dani 26, 46;
CP 1 g/m2 i.v. (1 h), days 26, 46;
CP 1 g/m² i.v. (1 h), dani 26, 46;
CP 1.2 g/m2 i.v. (3 h), day 1;
CP 1,2 g/m2 i.v. (3 h), dan 1;
CP 1.2 g/m2 i.v. (3 h), day 1;
CP 1,2 g/m² i.v. (3 h), dan 1;
CP 1.2 g/m2 i.v. (3 h), day 1; aunorubicin 60 mg/m2 i.v. (1 h), days 1-3;
CP 1,2 g/m² i.v. (3 h), dan 1;
CP 200 mg/ m2 i.v., days 3, 4, 5;
CP 200 mg/m2 i.v., dani 3, 4, 5;
CP 200 mg/ m2 i.v., days 3-5; MTX 15mg intrathecal, day 1
CP 200 mg/m2 i.v., dani 3-5;
CP 200 mg/m2 i.v., days 3, 4, 5;
CP 200 mg/m2 i.v., dani 3, 4, 5;
CP 200 mg/m2 i.v., days 3, 4, 5;
CP 200 mg/m² i.v., dani 3, 4, 5;
CP 200 mg/m2 i.v., days 3-5;
CP 200 mg/m2 i.v., dani 3-5;
CP 200 mg/m2 i.v., days 3-5;
CP 200 mg/m² i.v., dani 3-5;
CP 750 mg/m2 i.v., days 1, 8;
CP 750 mg/m2 i.v., dani 1, 8;
CP A or B
CP A ili B
CP classes
CP stadij
CP-AI-006 was an open-label follow-on study to CP-AI-005 and CP-AI-007 evaluating the safety of repeated exposure to aztreonamand the effect on disease-related endpoints over multiple 28-day courses.
CP-AI-006 je bilo otvoreno ispitivanje nastavka liječenja nakon ispitivanja CP-AI-005 i CP-AI-007 kojim se procjenjivala sigurnost ponavljane izloženosti aztreonamu i učinak na ishode povezane s bolešću tijekom više 28-dnevnih kura.
CP-Pharma Handelsgesellschaft mbH, Germany
CP-Pharma Handelsgesellschaft mbH Njemačka
CPB7.5+
CPB7,5+
CPK elevations and rhabdomyolysis: CPK elevations of any grade were observed in 23-26% of patients in both regimens.
Povišenja CPK-a i rabdomioliza: povišenja CPK-a bilo kojeg stupnja primijećena su u 23 – 26 % bolesnika u oba režima.
CPK increase is labelled as a common ADR in section 4.8 of the SmPC of leflunomide (Arava).
Povećanje vrijednosti CPK navedeno je kao česta nuspojava u dijelu 4.8 sažetka opisa svojstava lijeka za leflunomid (Arava).
CPK increases in association with rhabdomyolysis were reported in less than 1% of patients.
Povišenja CPK-a povezana s rabdomiolizom prijavljena su u manje od 1 % bolesnika.
CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) in patients who are at higher risk of developing myopathy.
U bolesnika s povećanim rizikom od razvoja miopatije CPK treba češće kontrolirati (npr. svaka 2-3 dana tijekom najmanje prva dva tjedna terapije).
CPM (250 mg/m2/dose q12h x 4 doses, iv): Days 3 and 4
CPM (250 mg/m2/doza svakih 12 sati x 4 doze, i.v.): Dani 3 i 4
CPM (250 mg/m2/dose q12h x 4 doses, IV): days 3 and 4
CPM (250 mg/m²/doza svakih 12 sati x 4 doze, i.v.): dani 3 i 4
CPM (300 mg/m2, IV): days 29-33 MESNA IV days 29-33
CPM (300 mg/m2, i.v.): dani 29-33 MESNA i.v., dani 29-33
CPM (300 mg/m2, IV): days 29-33 MESNA IV days 29-33
CPM (300 mg/m², i.v.): dani 29-33 MESNA i.v.: dani 29-33
CPM (300 mg/m2/day, IV): days 22-26
CPM (300 mg/m²/dan, i.v.): dani 22-26
Cpredose μg /mL
Cprije početka liječenja μg /mL
Cpredose μg /mL
Cprije početka lječenja μg /mL
CPT Class C cirrhosis pre-transplant CPT Class B or C post-transplant
Ciroza CPT stadija C prije transplantacije
CR + CRp + PR
KR + KRt + PR
CR 2 mg total dose i.v., days 1, 8, 15, 22;
VCR 2 mg ukupna doza i.v., dani 1, 8, 15, 22;
CR = complete remission; CRp = complete remission with incomplete platelet recovery, EFS = event-free survival, PFS = progression-free survival, OR = odds ratio, HR = hazard ratio
CR = potpuna remisija; CRp = potpuna remisija s nepotpunim oporavkom trombocita EFS = preživljenje bez događaja, PFS = preživljenje bez progresije bolesti, OR = omjer izgleda (vjerojatnosti), HR = omjer hazarda
CR rates
CR stope
CR with MRD Negativity (% of CR)
CR s negativnim nalazom na MRD (% CR-a)
CR+nCR
14,6 (10,4, 19,7)
CR+nCR
29 (26)d
CR+nCR+ PR+MR
CR+nCR+PR+M R
CR+nCR+ PR+MR
CR+nCR+PR+MR
CR+nCR+VGPR+PR
CR+nCR
CR+PR+MR **CR=CR, (IF-); nCR=CR (IF+)
CR+PR+MR **CR=CR, (IF-); nCR=CR (IF+)
Cr: creatinine; ULN: upper limit of normal
Cr: kreatinin; GGN: gornja granica normale
CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=Hazard Ratio;
CR=Kompletni odgovor; CRu=Nepotvrđeni kompletni odgovor; PR=Djelomični odgovor; CI=Interval pouzdanosti, HR=Omjer hazarda;
CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=Hazard Ratio; OR=Odds Ratio; ITT=Intent to Treat
CR=Kompletni odgovor; CRu=Nepotvrđeni kompletni odgovor; PR=Djelomični odgovor; CI=Interval pouzdanosti, HR=Omjer hazarda; OR=Omjer izgleda; ITT=Populacija namijenjena za liječenje
CR=Complete Response; nCR=near Complete response PR=Partial Response; MR=Minimal response
CR=Kompletni odgovor; nCR=blizu kompletnog odgovora PR=Parcijalni odgovor; MR=Minimalni odgovor
CR=complete response; PR=partial response
CR=potpun odgovor; PR=djelomičan odgovor
Cracking of the corner of the mouth, swollen gums, salivary gland pain
Pucanje kože u kutu usnica, otečene desni, bol u žlijezdama slinovnicama
CRAD001C2485: This was a prospective, open-label, single-arm phase II study of everolimus in patients with SEGA (n=28).
CRAD001C2485: Ovo je bilo prospektivno, otvoreno ispitivanje faze II s jednom skupinom za ispitivanje everolimusa u bolesnika sa SEGA-om (n=28).
cramps and muscle pains skin rash or ‘hives’ anywhere on the body
grčevi i bolovi u mišićima kožni osip ili “koprivnjača” bilo gdje na tijelu
cranial
kranijalna
Cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed in patients receiving BLINCYTO, especially in patients with prior treatment with cranial irradiation and anti-leukaemic chemotherapy (including systemic high dose methotrexate or intrathecal cytarabine).
U bolesnika u kojih se primjenjuje BLINCYTO, pogotovo u bolesnika prethodno liječenih zračenjem glave i kemoterapijom protiv leukemije (uključujući sistemsku primjenu visokih doza metotreksata ili intratekalnu primjenu citarabina) opažene su promjene nalaza MR-a glave (magnetska rezonancija) koje pokazuju leukoencefalopatiju.
cranial neuropathy8,
kranijalna
CrCL 60-89 mL/min (n=59), moderate renal impairment, CrCL 30-59 mL/min (n=22), and severe renal impairment CrCL <30 mL/min (n=3).
CrCL ≥90 ml/min (n= 213), blagim oštećenjem funkcije bubrega, CrCL 60-89 ml/min (n= 59), umjerenim oštećenjem funkcije bubrega, CrCL 30-59 ml/min (n= 22) i teškim oštećenjem funkcije bubrega CrCL <30 ml/min (n= 3).
CrCL < 15 mL/min), to use the correct Lixiana dose in patients with CrCL 15 – 50 mL/min (30 mg once daily), in patients with CrCL > 50 mL/min (60 mg once daily) and when deciding on the use of Lixiana in patients with increased creatinine clearance (see section 4.4).
CrCL < 15 ml/min) i primijenila ispravna doza Lixiane u bolesnika s CrCL 15 – 50 ml/min (30 mg jedanput na dan), u bolesnika s CrCL > 50 ml/min (60 mg jedanput na dan) te kad se odlučuje o primjeni Lixiane u bolesnika s povećanim klirensom kreatinina (vidjeti dio 4.4).
CrCL < 30 mL/min ).
CrCL < 30 mL/min).
CrCL < 30 mL/min) (see sections 4.3, 4.4 and 5.2).
CrCL < 30 mL/min) (vidjeti dijelov 4.3, 4.4 i 5.2).
CrCL < 30 mL/min) (see sections 4.3, 4.4 and 5.2).
CrCL < 30 mL/min) (vidjeti dijelove 4.3, 4.4 i 5.2).
CrCl <70 mL/min (n=214)
CrCl < 70 ml/min (n=214)
CrCl must be calculated at the beginning of every cycle before the start of treatment with Teysuno on Day 1.
CrCl treba izračunati na početku svakog ciklusa na prvi dan ciklusa prije početka liječenja lijekom Teysuno.
CrCL should be closely monitored and the dose adjusted according to changing renal function c The dose administered every 8 hours should not exceed 300 mg d The dose administered every 8 hours should not exceed 200 mg
CrCL treba pomno pratiti i dozu prilagoditi promjenama bubrežne funkcije c Doza koja se primjenjuje svakih 8 sati ne smije prelaziti 300 mg d Doza koja se primjenjuje svakih 8 sati ne smije prelaziti 200 mg
CrCL ≥ 30-< 50 mL/min, start VKA 2 days before discontinuing dabigatran etexilate
CrCL ≥ 30 -< 50 mL/min, početi VKA 2 dana prije prekida dabigatraneteksilata
CrCL ≥ 30-< 50 mL/min, start VKA 2 days before discontinuing dabigatran etexilate
CrCL ≥ 30-< 50 mL/min, početi VKA 2 dana prije prekida dabigatraneteksilata
CrCL ≥ 50 mL/min, start VKA 3 days before discontinuing dabigatran etexilate
CrCL ≥ 50 mL/min, početi VKA 3 dana prije prekida dabigatraneteksilata
CrCl ≥70 mL/min (n=227)
CrCl ≥ 70 ml/min (n=227)
Cream
krema
Cream 15 g
Krema 15 g
Creatine phosphokinase (CPK) elevations
Povišene vrijednosti kreatin fosfokinaze
Creatine phosphokinase (CPK) elevations
povišene vrijednosti kreatin fosfokinaze (CPK)
Creatine phosphokinase and myopathy
Kreatin fosfokinaza i miopatija
Creatinine <2.5 mg/dl
Kreatinin < 2,5 mg/dl
Creatinine clearance
Klirens kreatinina (ml/min/1,73 m2)
Creatinine Clearance (CLcr) (ml/min)
Klirens kreatinina (CLcr) (ml/min)
Creatinine clearance (CrCl) must be determined for every cycle before the start of treatment on Day 1.
Mora se odrediti klirens kreatinina (CrCl) za svaki ciklus prije početka liječenja, na 1. dan ciklusa.
Creatinine clearance (ml/min)
Klirens kreatinina (ml/min )
Creatinine clearance (ml/min/1.73 m2)
Klirens kreatinina (ml/ min/1,73 m2)
Creatinine clearance (ml/min/1.73 m2)
Klirens kreatinina(ml/mi n/1,73m2)
Creatinine clearance (ml/min/1.73m2 )
Klirens kreatinina (ml/min/1,73m2)
Creatinine clearance (ml/min/1.73m2)
Klirens kreatinina(ml/mi n/1,73m2)
Creatinine clearance < 15 mL/min (or creatinine clearance decreases to ≤ 50% of baseline) or need for dialysis
Klirens kreatinina < 15 ml/min (ili klirens kreatinina smanjen na ≤ 50% od početne vrijednosti) ili potreba za dijalizom (vidjeti dio 4.4)
Creatinine clearance and/or plasma cystatin C
Klirens kreatinina i/ili cistatin C u plazmi
Creatinine clearance decreased**
smanjen klirens kreatinina